Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 1:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Adacel Clear all
Recruiting Phase 3 Interventional Accepts healthy volunteers

BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies

NCT07160244
View directory record Official record
Conditions
Healthy
Interventions
Multivalent Group B streptococcus vaccine, Placebo, Infanrix hexa, Prevenar 20, Pediarix, Prevnar 20, Infanrix
Biological
Lead sponsor
Pfizer
Industry
Eligibility
1 Day to 49 Years
Enrollment
6,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
119
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9

NCT00489970
View directory record Official record
Conditions
Acellular Pertussis, Tetanus, Diphtheria
Interventions
Taking of blood samples, Boostrix, Adacel
Procedure · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
28 Years to 73 Years
Enrollment
1,954 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
37
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Immune Response to Vaccines and Ixekizumab (LY2439821) in Healthy Participants

NCT02543918
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab, Boostrix®, Pneumovax®23
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
3
States / cities
Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 6, 2017 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™

NCT00802867
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis, Polio, Haemophilus Infection
Interventions
Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
989 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
19
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Not applicable Interventional

DTaP and Apnea/Bradycardia in Preterm Infants

NCT00482781
View directory record Official record
Conditions
Prolonged Apnea, Prolonged Bradycardia
Interventions
Infanrix, Pediatrix
Biological
Lead sponsor
American SIDS Institute
Other
Eligibility
56 Days to 60 Days
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
10
States / cities
Austell, Georgia • Marietta, Georgia • Belle Mead, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2007 · Synced Oct 28, 2026, 1:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rates of Pertussis Disease Among Persons Receiving Pentacel® or Other Pertussis Vaccines

NCT01129362
View directory record Official record
Conditions
Pertussis
Interventions
Pentacel® (DTaP-IPV/Hib), Other Pertussis Vaccines
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Up to 59 Months
Enrollment
1,195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety

NCT00263692
View directory record Official record
Conditions
Diphtheria, Acellular Pertussis, Tetanus
Interventions
Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 6 Years
Enrollment
401 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2004
U.S. locations
15
States / cities
Jonesboro, Arkansas • Fountain Valley, California • Oakland, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2011 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Results available

Tdap Vaccine in Post-Partum Women

NCT01711645
View directory record Official record
Conditions
Diphtheria, Pertussis, Tetanus
Interventions
Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2018 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Results available

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

NCT03530124
View directory record Official record
Conditions
Apnea, Apnea Neonatal, Prematurity
Interventions
PCV13, DTaP, HBV, IPV, Hib
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Weeks and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 28, 2026, 1:55 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

NCT00258882
View directory record Official record
Conditions
Pertussis
Interventions
Tetanus Toxoid, acellular pertussis, diphtheria toxoid
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
327,293 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
3
States / cities
Oakland, California • Aurora, Colorado • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 17, 2018 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects

NCT00369824
View directory record Official record
Conditions
Infections, Papillomavirus
Interventions
Different formulations of GSK Biologicals' HPV vaccine (580299), Menactra TM, Boostrix TM
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
11 Years to 18 Years · Female only
Enrollment
1,330 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
50
States / cities
Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2018 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

NCT00319553
View directory record Official record
Conditions
Pertussis, Tetanus, Diphtheria
Interventions
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed, BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
11 Years to 18 Years
Enrollment
647 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
10
States / cities
Annapolis, Maryland • Baltimore, Maryland • Frederick, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine

NCT00662870
View directory record Official record
Conditions
Diphtheria, Tetanus, Whooping Cough, Polio, Haemophilus Influenzae Type b
Interventions
DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine), Pentacel: DTaP-IPV/Hib
Biological
Lead sponsor
Sanofi
Industry
Eligibility
42 Days to 84 Days
Enrollment
1,941 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2004
U.S. locations
26
States / cities
Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

NCT01311557
View directory record Official record
Conditions
Tetanus, Diphtheria, Pertussis
Interventions
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
Biological
Lead sponsor
Sanofi
Industry
Eligibility
10 Years to 11 Years
Enrollment
1,302 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
34
States / cities
Chandler, Arizona • Jonesboro, Arkansas • Little Rock, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Results available

Prospective Trial of Vaccine Responses in Childhood Cancer Survivors

NCT00505063
View directory record Official record
Conditions
Childhood Cancer, Multiple Diseases
Interventions
Immunization Schedule patients <7 years., Immunization Schedule patients > or = to 7 years and <11 years of age, Immunization Schedule patients > or = to 11 years of age
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
2 Years to 18 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Diphtheria, Pertussis and Tetanus (Tdap) Viruses Followed by a 2nd Dose of the RSV Vaccine to Healthy Non-Pregnant Women

NCT04138056
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 formulation 3, RSVPreF3 formulation 2, Boostrix-ex-US, Boostrix-US, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2024 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®

NCT00258895
View directory record Official record
Conditions
Diphtheria, Tetanus, Pertussis
Interventions
DAPTACEL®: DTaP
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
4 Years to 6 Years
Enrollment
649 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
22
States / cities
Fayetteville, Arkansas • Jonesboro, Arkansas • Little Rock, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety, Tolerability, and Immunogenicity of A Multivalent Group B Streptococcus Vaccine When Administered Concomitantly With Tdap in Healthy Nonpregnant Women

NCT04766086
View directory record Official record
Conditions
Group B Streptococcus Infections
Interventions
Multivalent Group B streptococcus vaccine, Tetanus, diphtheria, and acellular pertussis vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
12
States / cities
Newton, Kansas • Omaha, Nebraska • Las Vegas, Nevada + 8 more
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants

NCT00474526
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
Meningococcal ACWY Conjugate Vaccine, DTaP-IPV-HBV, Hib, Rotavirus, Pneumococcal 7-valent Conjugate Vaccine, HAV, MMR-V, DTaP
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
2 Months to 2 Months
Enrollment
4,545 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
53
States / cities
Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2018 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Tdap Vaccine Safety for Plasma Donors

NCT04142983
View directory record Official record
Conditions
Tetanus
Interventions
Adacel
Biological
Lead sponsor
GCAM Inc.
Industry
Eligibility
18 Years to 63 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Eagle Pass, Texas • Laredo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 28, 2026, 1:55 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age

NCT05169905
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT vaccine, dTpa vaccine
Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Years to 49 Years · Female only
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami, Florida • Beaumont, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 28, 2026, 1:55 PM EDT